Blind sampling: difference between revisions
Diff·revision 11 → 12·08:03, 12 Feb 2025
Difference between revision 11 and revision 12 of Blind sampling. 13 lines changed; the page grew by 676 bytes.
| Revision 11 — 05:03, 23 Jan 2025 BatchNumberBede (talk) add the second-opinion point: two services, one lot, is a stronger record 4,974 bytes +153 | Revision 12 — 08:03, 12 Feb 2025 Chromatokid (talk) add the retest interval and what triggers one 5,650 bytes +676 | ||
|---|---|---|---|
| 34 | In the research-compound sector there is no obligation and no authority. The parties with a reason to test are purchasers, who are testing their own material because they want to know about their own material, and testing services, which test what is sent to them. Neither is positioned to run a sampling plan.{{r|reports}} | 34 | In the research-compound sector there is no obligation and no authority. The parties with a reason to test are purchasers, who are testing their own material because they want to know about their own material, and testing services, which test what is sent to them. Neither is positioned to run a sampling plan.{{r|reports}} |
| 35 | 35 | ||
| + | 36 | === What a non-blind result still establishes === | |
| + | 37 | The limitation is not a reason to disregard the reports; it is a reason to state what they support. A non-blind, purchaser-selected result on a single vial establishes, without qualification: | |
| + | 38 | ||
| + | 39 | * that the material in that vial gave that figure under the stated method; | |
| + | 40 | * that a [[Certificate of analysis|certificate]] accompanying it either did or did not agree with an independent determination on the same sample; | |
| + | 41 | * that the vial did or did not carry a lot identifier matching its certificate and invoice. | |
| + | 42 | ||
| 36 | == References == | 43 | == References == |
| 37 | {{reflist}} | 44 | {{reflist}} |
| ⋮ | ⋮ | ||
| 39 | <ref name="reports">Purchaser-submitted test reports held by PeptidePedia, 2024–2026, together with the submission metadata recorded with them. None arose from a documented sampling procedure.</ref> | 46 | <ref name="reports">Purchaser-submitted test reports held by PeptidePedia, 2024–2026, together with the submission metadata recorded with them. None arose from a documented sampling procedure.</ref> |
| 40 | <ref name="gmp">World Health Organization, ''Good Manufacturing Practices for Pharmaceutical Products: Main Principles'', WHO Technical Report Series. Treats sampling as a quality-system responsibility distinct from the analysis performed on the sample.</ref> | 47 | <ref name="gmp">World Health Organization, ''Good Manufacturing Practices for Pharmaceutical Products: Main Principles'', WHO Technical Report Series. Treats sampling as a quality-system responsibility distinct from the analysis performed on the sample.</ref> |
| + | 48 | ||
| + | 49 | == See also == | |
| + | 50 | * [[Chain of custody]] | |
| + | 51 | * [[Third-party testing]] | |
| + | 52 | * [[Certificate of analysis]] | |
| + | 53 | * [[Lot traceability]] | |
| 41 | 54 | ||
| 42 | {{DEFAULTSORT:Blind sampling}} | 55 | {{DEFAULTSORT:Blind sampling}} |